Bristol-Myers Squibb Co’s recent filing unveils that its EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit acquired Company’s shares for reported $0.2 million on Apr 25 ’25. In the deal valued at $47.58 per share,4,250 shares were bought. As a result of this transaction, Hirawat Samit now holds 83,513 shares worth roughly $3.88 million.
Then, BOERNER CHRISTOPHER S. bought 2,000 shares, generating $110,096 in total proceeds. Upon buying the shares at $55.05, the Chief Executive Officer now owns 104,626 shares.
Before that, Hirawat Samit bought 1,823 shares. Bristol-Myers Squibb Co shares valued at $100,000 were divested by the EVP,Chief Med.Offr.,Drug Dev. at a price of $54.84 per share. As a result of the transaction, Hirawat Samit now holds 63,932 shares, worth roughly $2.97 million.
Piper Sandler initiated its Bristol-Myers Squibb Co [BMY] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late April with a ‘”a Neutral”‘ rating. Jefferies also remained covering BMY and has increased its forecast on December 16, 2024 with a “Buy” recommendation from previously “Hold” rating.
Price Performance Review of BMY
On Friday, Bristol-Myers Squibb Co [NYSE:BMY] saw its stock fall -0.92% to $46.45. Over the last five days, the stock has lost -8.15%. Bristol-Myers Squibb Co shares have fallen nearly -17.87% since the year began. Nevertheless, the stocks have risen 5.47% over the past one year. While a 52-week high of $63.33 was reached on 03/11/25, a 52-week low of $39.35 was recorded on 05/09/25. SMA at 50 days reached $55.01, while 200 days put it at $54.21.
Levels Of Support And Resistance For BMY Stock
The 24-hour chart illustrates a support level at 46.14, which if violated will result in even more drops to 45.83. On the upside, there is a resistance level at 46.94. A further resistance level may holdings at 47.43. The Relative Strength Index (RSI) on the 14-day chart is 30.31, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.70, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.00%. Stochastics %K at 10.09% indicates the stock is a buying.
The most recent change occurred on November 15, 2024 when Wolfe Research began covering the stock and recommended ‘”a Peer perform”‘ rating .
